Publications by authors named "Hendrika Adriana Linda Kievit"
BACKGROUND: Whether infliximab therapy can be successfully discontinued after patients with Crohn’s disease have attained sustained, clinical, biochemical, and endoscopic remission is unknown. METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled withdrawal study of infliximab in patients with Crohn’s disease who were in clinical, biochemical, and endoscopic remission after standard infliximab maintenance therapy for at least 1 year. Patients were randomly assigned 1:1 to continue infliximab therapy or to receive matching placebo for 48 weeks.
View Article and Find Full Text PDFBackground: Inflammatory bowel disease (IBD) places a significant burden on health-care systems because of its chronicity and need for expensive therapies and surgery. With increasing use of biological therapies, contemporary data on IBD health-care costs are important for those responsible for allocating resources in Europe. To our knowledge, no prospective long-term analysis of the health-care costs of patients with IBD in the era of biologicals has been done in Europe.
View Article and Find Full Text PDFBackground And Aim: A definitive diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) is not always possible, and a proportion of patients will be diagnosed as inflammatory bowel disease unclassified (IBDU). The aim of the study was to investigate the prognosis of patients initially diagnosed with IBDU and the disease course during the following 5 years.
Methods: The Epi-IBD study is a prospective population-based cohort of 1289 IBD patients diagnosed in centers across Europe.
Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.
J Crohns Colitis
February 2019
Article Synopsis
- This study investigated the long-term outcomes of ulcerative colitis (UC) patients using a population-based cohort to understand the impact of modern treatments like biological therapy and immunomodulators over five years.
- Out of 717 patients tracked, 6% required colectomy, and 23% were hospitalized, with some patients showing disease progression or regression.
- Despite aggressive treatments, the overall disease outcomes (like colectomy rates) did not differ significantly from previous decades, but immunomodulators were linked to a lower risk of hospitalizations.
Article Synopsis
- - The Epi-IBD study followed 488 patients with Crohn's disease from various European centers to evaluate their outcomes over five years, focusing on surgery, hospitalizations, and progression of the disease.
- - Of the patients studied, 22% underwent surgery, and 36% were hospitalized, with about 14% experiencing worsening disease conditions, yet outcomes between Western and Eastern European patients were largely similar.
- - Significant differences in treatment approaches were observed, with Western Europeans more often receiving biological therapies and immunomodulators, which helped lower surgery and hospitalization risks, but did not ultimately change disease progression rates across regions.